Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in diabetes

Webinar

Watch on-demand

EMPEROR-Preserved

Join cardiologist Lars Rydén, endocrinologist Alice Cheng, and primary care practitioner Kevin Saunders to discuss the diagnosis and management of people with type 2 diabetes and shortness of breath in primary care, and how the positive findings of EMPEROR-Preserved will now shape the care of these patients. Watch now

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

Stefano Del Prato

Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

New additions to the Adis Journal Club

Drugs Journal

Browse October's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Tirzerpatide

10-22-2021 | Tirzepatide | Video

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

IN FOCUS | Hypoglycemia

10-13-2021 | Hypoglycemia | View from the clinic | Article

Endemic hypoglycemia

In the final article in this series, Sanjay Kalra highlights region-specific causes of hypoglycemia requiring a tailored management approach.

IN FOCUS | Chronic kidney disease

09-15-2021 | ESC 2021 | Conference coverage | Video

FIGARO: Where will finerenone fit into diabetic kidney disease treatment?

David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors.

IN FOCUS | SGLT2 inhibitors

10-07-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

IN FOCUS | Cardiovascular disorders

10-22-2021 | Tirzepatide | Video

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

ESC Congress 2021 coverage

27 – 30 August: Browse all of the latest coverage


IN FOCUS | GLP-1 receptor agonists

10-07-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

IN FOCUS | Mental health & psychosocial care

07-21-2021 | Disordered eating | News

Eating disorders tied to increased DKA, mortality risk in young people with type 1 diabetes

The presence of an eating disorder diagnosis significantly increases the risk for diabetic ketoacidosis and all-cause mortality in adolescents and young adults with type 1 diabetes, shows a population-based study.

Addressing suicide risk in diabetes

Learn about rates and risk, underlying psychological factors, and practical actions to support patients.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

IN FOCUS | Metformin & oral combination therapies

09-29-2021 | EASD 2021 | Conference coverage | News

TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

IN FOCUS | Diabetes devices & technology

06-02-2021 | ATTD 2021 | Conference coverage | News

Studies support wider CGM access in type 2 diabetes

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

IN FOCUS | Obesity & lifestyle interventions

10-19-2021 | Tirzepatide | News

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

Podcasts

Interviews with experts on diabetes patient care

Image Credits